Rani Therapeutics, LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- $181.4M
- Website
- http://rcub.ac.in/
Study Evaluating PK of Ustekinumab Administered Orally Via RaniPillâ„¢ Capsule
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT05890118
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
Study Evaluating PK of PTH Administered Orally Via RaniPillâ„¢ Capsule
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05164614
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
Pill Swallow Study
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 152
- Registration Number
- NCT04911296
- Locations
- 🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States
A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- RANI Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT03798912
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Australia
© Copyright 2024. All Rights Reserved by MedPath